AVERT-VT: Ablation at Virtual-hEart pRedicted Targets for VT

Sponsor
Johns Hopkins University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03536052
Collaborator
(none)
30
1
1
46.4
0.6

Study Details

Study Description

Brief Summary

The goal of this study is to test the efficacy of the new imaging/simulation ("virtual heart") approach for determining the optimal ablation sites in patients with VT, which render post-infarction VT non-inducible. The study will test both the acute outcome of the ablation procedure, and the effect the use of the predicted targets has upon procedure time.

Condition or Disease Intervention/Treatment Phase
  • Device: Virtual Heart Guided Ablation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Ablation at Virtual-hEart pRedicted Targets for VT
Actual Study Start Date :
Oct 20, 2018
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Virtual Heart Guided Ablation

Device: Virtual Heart Guided Ablation
If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.

Outcome Measures

Primary Outcome Measures

  1. Ventricular Tachycardia Inducibility [time of procedure]

    Following ablation, inducibility of VT will be determined using programmed electrical stimulation

Secondary Outcome Measures

  1. Freedom from Ventricular Tachycardia [1 year]

    Long term Freedom of Spontaneous Ventricular Tachycardia

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Eligible patients must be at least 18 years old at the time of enrollment.

  • A Pre-Op cardiac MRI including late gadolinium enhancement (LGE) must be performed prior to ablation. As Johns Hopkins University (JHU) performs MRIs with implantable cardioverter defibrillator (ICD) or pacemaker implanted, patients with these devices may be enrolled.

  • Eligible patients must suffer from VT, thought to be secondary to structural heart disease (scarring).

  • Eligible patients must be determined to be suitable candidates for ablation to treat VT by their cardiologist and/or electrophysiologists regardless of this protocol.

Exclusion Criteria:
  • Patients with Glomerular Filtration Rate (GFR) < 30 mL/min should not be enrolled in the study due to the use of intravenous gadolinium as an MRI contrast agent

  • If a pre-procedure MRI cannot or likely will not be performed for any reason (such as claustrophobia), the patient must be excluded.

  • Pregnant women may not participate in the study because gadolinium MRI contrast is contraindicated in these patients.

  • Any subject that, during the course of the pre-procedure imaging, is discovered to have VT not related to scarring, he/she must be de-enrolled from the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Johns Hopkins Baltimore Maryland United States 21287

Sponsors and Collaborators

  • Johns Hopkins University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT03536052
Other Study ID Numbers:
  • IRB00141401
First Posted:
May 24, 2018
Last Update Posted:
Sep 16, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 16, 2021